3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
16
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Lung Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Oropharyngeal Neoplasms
4
Multiple Myeloma
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Neuroendocrine Tumors
3
Neoplasm Metastasis
3
Lymphoma, Large B-Cell, Diffuse
3
Anus Neoplasms
3
Testicular Neoplasms
2
Solid Tumor
2
Pheochromocytoma
2
Paraganglioma
2
Pancreatic Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Laryngeal Neoplasms
2
Interventions
Doxorubicin
5
pembrolizumab
4
Specimen Handling
4
Radiotherapy
4
Radiation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
CTLA-4 Antigen
3
Biopsy
3
cabozantinib
2
Ifosfamide
2
tremelimumab
1
talimogene laherparepvec
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
liposomal doxorubicin
1
futibatinib
1
fludarabine
1
eribulin
1
durvalumab
1
avelumab
1
aldesleukin
1
X-Rays
1
Trabectedin
1
Standard of Care
1
Quality of Life
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Fluorodeoxyglucose F18
×
1 year
×
Clear all
No trials found.